TheProfitWatch

ETNB - 89bio, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
14.78 0.03 (0.2%) --- --- --- 0.02 (0.14%) -0.01 (-0.07%) 0.0 (0.0%) 0.02 (0.11%)

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Category: PHARMACEUTICAL PREPARATIONS
Market Period: AfterHours

Earnings & Ratios

Basic EPS:
-0.71
Diluted EPS:
-0.71
Basic P/E:
-20.8592
Diluted P/E:
-20.8592
RSI(14) 1m:
73.89
VWAP:
14.81
RVol:
0.2832

Events

Period Kind Movement Occurred At

Related News